Core Viewpoint - The announcement highlights that Jiangsu Shenhua Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huaren Health, has received the acceptance notice for the drug registration application of Fumaric Acid Vonoprazan Tablets from the National Medical Products Administration of China, indicating a significant step towards market entry for this new medication [1] Group 1: Drug Information - Fumaric Acid Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that can reversibly inhibit the H+/K+-ATPase on gastric parietal cells in a potassium-competitive manner without relying on an acidic environment [1] - The drug is stable in highly acidic environments and can rapidly, effectively, and durably suppress gastric acid secretion from gastric parietal cells, significantly reducing the occurrence of nighttime gastric acid elevation [1] - It was officially approved for marketing in China on December 18, 2019, for the treatment of gastroesophageal reflux disease, making it the first P-CAB to enter the Chinese market [1]
华人健康：全资子公司收到药品注册受理通知书